- Home
- TKNO vs CRVS Comparison
TKNO vs CRVS Comparison
Compare TKNO & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKNO
- CRVS
- Stock Information
- Founded
- TKNO 1996
- CRVS 2014
- Country
- TKNO United States
- CRVS United States
- Employees
- TKNO N/A
- CRVS N/A
- Industry
- TKNO Medicinal Chemicals and Botanical Products
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- TKNO Health Care
- CRVS Health Care
- Exchange
- TKNO Nasdaq
- CRVS Nasdaq
- Market Cap
- TKNO 256.9M
- CRVS 305.4M
- IPO Year
- TKNO 2021
- CRVS 2016
- Fundamental
- Price
- TKNO $4.35
- CRVS $5.75
- Analyst Decision
- TKNO
- CRVS Strong Buy
- Analyst Count
- TKNO 0
- CRVS 4
- Target Price
- TKNO N/A
- CRVS $15.00
- AVG Volume (30 Days)
- TKNO 221.4K
- CRVS 494.0K
- Earning Date
- TKNO 08-07-2025
- CRVS 08-07-2025
- Dividend Yield
- TKNO N/A
- CRVS N/A
- EPS Growth
- TKNO N/A
- CRVS N/A
- EPS
- TKNO N/A
- CRVS N/A
- Revenue
- TKNO $38,923,000.00
- CRVS N/A
- Revenue This Year
- TKNO $9.52
- CRVS N/A
- Revenue Next Year
- TKNO $15.20
- CRVS N/A
- P/E Ratio
- TKNO N/A
- CRVS N/A
- Revenue Growth
- TKNO 11.40
- CRVS N/A
- 52 Week Low
- TKNO $4.00
- CRVS $2.54
- 52 Week High
- TKNO $10.37
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- TKNO 43.35
- CRVS 65.10
- Support Level
- TKNO $4.22
- CRVS $5.28
- Resistance Level
- TKNO $4.94
- CRVS $5.64
- Average True Range (ATR)
- TKNO 0.29
- CRVS 0.30
- MACD
- TKNO -0.00
- CRVS 0.03
- Stochastic Oscillator
- TKNO 16.75
- CRVS 77.70
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).